

Frank Buttgereit

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8394532/publications.pdf>

Version: 2024-02-01

250
papers

20,958
citations

19657

61
h-index

11052

137
g-index

265
all docs

265
docs citations

265
times ranked

19503
citing authors

#	ARTICLE	IF	CITATIONS
1	How to taper glucocorticoids in inflammatory rheumatic diseases? A narrative review of novel evidence in rheumatoid arthritis, systemic lupus erythematosus, and giant cell arteritis. <i>Joint Bone Spine</i> , 2022, 89, 105285.	1.6	6
2	MIF does only marginally enhance the pro-regenerative capacities of DFO in a mouse-osteotomy-model of compromised bone healing conditions. <i>Bone</i> , 2022, 154, 116247.	2.9	11
3	A new perspective is needed for positive selection of germinal center B cells with higher-affinity B cell receptors. <i>Cellular and Molecular Immunology</i> , 2022, 19, 145-146.	10.5	2
4	Glucocorticoids Are Not Associated with Bone Mineral Density in Patients with Polymyalgia Rheumatica, Giant Cell Arteritis and Other Vasculitidesâ€”Cross-Sectional Baseline Analysis of the Prospective Rh-GIOP Cohort. <i>Cells</i> , 2022, 11, 536.	4.1	4
5	The safety of glucocorticoids in the treatment of inflammatory rheumatic disease: new evidence. <i>Current Opinion in Rheumatology</i> , 2022, 34, 179-186.	4.3	4
6	Optimization of a Tricalcium Phosphate-Based Bone Model Using Cell-Sheet Technology to Simulate Bone Disorders. <i>Processes</i> , 2022, 10, 550.	2.8	1
7	Metabolic reprogramming of synovial fibroblasts in osteoarthritis by inhibition of pathologically overexpressed pyruvate dehydrogenase kinases. <i>Metabolic Engineering</i> , 2022, 72, 116-132.	7.0	8
8	Systematic literature review of observational cohorts and clinical trials into the success rate of glucocorticoid discontinuation after their use as bridging therapy in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 937-943.	0.9	14
9	The Anti-Glucocorticoid Receptor Antibody Clone 5E4: Raising Awareness of Unspecific Antibody Binding. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5049.	4.1	1
10	Looking ahead: giant-cell arteritis in 10 years time. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2210963.	2.7	10
11	Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 925-936.	0.9	59
12	Frequently Used Patient-Reported Outcome Measures of General Physical Function Were Highly Correlated With a Multitask Performance Outcome Test Battery. <i>Value in Health</i> , 2022, 25, 1752-1759.	0.3	3
13	Controversies in rheumatology: maintenance therapy with low-dose glucocorticoids in rheumatoid arthritis. <i>Rheumatology</i> , 2022, 62, 35-41.	1.9	3
14	Optimising both disease control and glucocorticoid dosing is essential for bone protection in patients with rheumatic disease. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1313-1322.	0.9	25
15	Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 518-526.	0.9	54
16	Reply to: What could a new disease activity score for polymyalgia rheumatica do better?. <i>Nature Reviews Rheumatology</i> , 2021, 17, 185-186.	8.0	2
17	Glucocorticoids: surprising new findings on their mechanisms of actions. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 137-139.	0.9	11
18	Barriers and potential solutions in the recruitment and retention of older patients in clinical trialsâ€”lessons learned from six large multicentre randomized controlled trials. <i>Age and Ageing</i> , 2021, 50, 1988-1996.	1.6	17

#	ARTICLE	IF	CITATIONS
19	Response to: "Correspondence on "Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries"™ by Nokhatha et al. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e171-e171.	0.9	4
20	New insights into the fascinating world of glucocorticoids: the dexamethasone-miR-342-Rictor axis in regulatory T cells. <i>Cellular and Molecular Immunology</i> , 2021, 18, 520-522.	10.5	0
21	Quantification of morning stiffness to assess disease activity and treatment effects in rheumatoid arthritis. <i>Rheumatology</i> , 2021, 60, 5282-5291.	1.9	2
22	A novel approach to improve detection of glucocorticoid doping in sport with new guidance for physicians prescribing for athletes. <i>British Journal of Sports Medicine</i> , 2021, 55, 631-642.	6.7	14
23	Fracture Healing Research"Shift towards In Vitro Modeling?. <i>Biomedicines</i> , 2021, 9, 748.	3.2	16
24	Surface AMP deaminase 2 as a novel regulator modifying extracellular adenine nucleotide metabolism. <i>FASEB Journal</i> , 2021, 35, e21684.	0.5	3
25	Hydroxychloroquine in patients with inflammatory and erosive osteoarthritis of the hands: results of the OA-TREAT study" a randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial. <i>RMD Open</i> , 2021, 7, e001660.	3.8	19
26	GCA management guidelines " vive la diff�rence?. <i>Nature Reviews Rheumatology</i> , 2021, 17, 649-650.	8.0	4
27	Systematic review on the reporting accuracy of experimental details in publications using mouse femoral fracture models. <i>Bone</i> , 2021, 152, 116088.	2.9	6
28	A Human Osteochondral Tissue Model Mimicking Cytokine-Induced Key Features of Arthritis In Vitro. <i>International Journal of Molecular Sciences</i> , 2021, 22, 128.	4.1	5
29	Production of IL-6 and Phagocytosis Are the Most Resilient Immune Functions in Metabolically Compromised Human Monocytes. <i>Frontiers in Immunology</i> , 2021, 12, 730672.	4.8	4
30	The Experiences of Functioning and Health of Patients With Primary Sj�gren's Syndrome: A Multicenter Qualitative European Study. <i>Frontiers in Medicine</i> , 2021, 8, 770422.	2.6	3
31	Association Between Participant Retention and the Proportion of Included Elderly People in Rheumatology Trials: Results From a Series of Exploratory Meta-Regression Analyses. <i>Arthritis Care and Research</i> , 2020, 72, 1490-1496.	3.4	2
32	2018 Update of the EULAR recommendations for the management of large vessel vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 19-30.	0.9	667
33	Can we shift the benefit"risk ratio of glucocorticoids?. <i>Lancet Rheumatology</i> , The, 2020, 2, e5-e6.	3.9	4
34	P235"Glucocorticoid dose is progressively reduced in Patients with rheumatoid arthritis (RA) receiving sarilumab: results from the open label EXTEND study. <i>Rheumatology</i> , 2020, 59, .	1.9	1
35	Reducing the Toxicity of Long-Term Glucocorticoid Treatment in Large Vessel Vasculitis. <i>Current Rheumatology Reports</i> , 2020, 22, 85.	4.7	9
36	Optimal temporal artery biopsy length for diagnosis of giant cell arteritis. <i>Lancet Rheumatology</i> , The, 2020, 2, e730-e732.	3.9	0

#	ARTICLE	IF	CITATIONS
37	Monitoring and long-term management of giant cell arteritis and polymyalgia rheumatica. <i>Nature Reviews Rheumatology</i> , 2020, 16, 481-495.	8.0	54
38	Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial. <i>Lancet</i> , The, 2020, 396, 267-276.	13.7	78
39	Challenges, collaboration, and innovation in rheumatology education during the COVID-19 pandemic: leveraging new ways to teach. <i>Clinical Rheumatology</i> , 2020, 39, 3535-3541.	2.2	24
40	Recruitment and Retention of Older People in Clinical Research: A Systematic Literature Review. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 2955-2963.	2.6	83
41	Polymyalgia Rheumatica and Giant Cell Arteritis. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 993.	7.4	34
42	Using subdomain-specific item sets affected PROMIS physical function scores differently in cardiology and rheumatology patients. <i>Journal of Clinical Epidemiology</i> , 2020, 127, 151-160.	5.0	5
43	European Guideline on IgG4-related digestive disease – UEG and SGF evidence-based recommendations. <i>United European Gastroenterology Journal</i> , 2020, 8, 637-666.	3.8	120
44	Macroscale mesenchymal condensation to study cytokine-driven cellular and matrix-related changes during cartilage degradation. <i>Biofabrication</i> , 2020, 12, 045016.	7.1	9
45	Views on glucocorticoid therapy in rheumatology: the age of convergence. <i>Nature Reviews Rheumatology</i> , 2020, 16, 239-246.	8.0	71
46	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary. <i>Rheumatology</i> , 2020, 59, 487-494.	1.9	56
47	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. <i>Rheumatology</i> , 2020, 59, e1-e23.	1.9	128
48	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 685-699.	0.9	1,860
49	Glucocorticoids in rheumatoid arthritis: current status and future studies. <i>RMD Open</i> , 2020, 6, e000536.	3.8	89
50	Glucocorticoid-trials in rheumatoid arthritis mostly study representative real-world patients: A systematic review and meta-analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1400-1405.	3.4	5
51	Functional Scaffold-Free Bone Equivalents Induce Osteogenic and Angiogenic Processes in a Human In Vitro Fracture Hematoma Model. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 1189-1201.	2.8	7
52	The in vitro human fracture hematoma model - a tool for preclinical drug testing. <i>ALTEX: Alternatives To Animal Experimentation</i> , 2020, 37, 561-578.	1.5	6
53	Impact of Janus Kinase Inhibition with Tofacitinib on Fundamental Processes of Bone Healing. <i>International Journal of Molecular Sciences</i> , 2020, 21, 865.	4.1	21
54	Response to the Letter to the Editor: Prevalence, Risk Factors and Assessment of Depressive Symptoms in Patients With Systemic Sclerosis. <i>Archives of Rheumatology</i> , 2020, 35, 460-461.	0.9	0

#	ARTICLE	IF	CITATIONS
55	The 70th anniversary of glucocorticoids in rheumatic diseases: the second youth of an old friend. <i>Rheumatology</i> , 2019, 58, 580-587.	1.9	20
56	Metabolism of T Lymphocytes in Health and Disease. <i>International Review of Cell and Molecular Biology</i> , 2019, 342, 95-148.	3.2	20
57	Glucocorticoidsâ€™ All-Rounders Tackling the Versatile Players of the Immune System. <i>Frontiers in Immunology</i> , 2019, 10, 1744.	4.8	170
58	Administration of Tramadol or Buprenorphine via the drinking water for post-operative analgesia in a mouse-osteotomy model. <i>Scientific Reports</i> , 2019, 9, 10749.	3.3	29
59	Prevalence, Risk Factors and Assessment of Depressive Symptoms in Patients With Systemic Sclerosis. <i>Archives of Rheumatology</i> , 2019, 34, 253-261.	0.9	12
60	Treat to Target. <i>Rheumatic Disease Clinics of North America</i> , 2019, 45, 549-567.	1.9	9
61	Association between changes in molecular biomarkers of cartilage matrix turnover and changes in knee articular cartilage: a longitudinal pilot study. <i>Journal of Experimental Orthopaedics</i> , 2019, 6, 19.	1.8	11
62	Fosdagrocorat (PF-04171327) versus prednisone or placebo in rheumatoid arthritis: a randomised, double-blind, multicentre, phase IIb study. <i>RMD Open</i> , 2019, 5, e000889.	3.8	27
63	An updated review of glucocorticoid-related adverse events in patients with rheumatoid arthritis. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 581-590.	2.4	30
64	2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1160-1166.	0.9	34
65	Hypoxia and mesenchymal stromal cells as key drivers of initial fracture healing in an equine in vitro fracture hematoma model. <i>PLoS ONE</i> , 2019, 14, e0214276.	2.5	24
66	OP0074â€™...TOFACITINIB PROMOTES FUNDAMENTAL PROCESSES OF BONE HEALING. , 2019, , .		0
67	SAT0068â€™...CIRCADIAN RHYTHMS OF IMMUNE SYSTEM IN HEALTHY INDIVIDUALS AND PATIENTS WITH RHEUMATOID ARTHRITIS. , 2019, , .		0
68	OP0030â€™...RANDOMIZED CONTROLLED 24-WEEK TRIAL EVALUATING THE SAFETY AND EFFICACY OF BLINDED TAPERING VERSUS CONTINUATION OF LONG-TERM PREDNISONE (5 MG/D) IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO ACHIEVED LOW DISEASE ACTIVITY OR REMISSION ON TOCILIZUMAB. , 2019, , .		5
69	FRIO284â€™...RESULTS OF A SYSTEMATIC LITERATURE REVIEW INFORMING THE 2018 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF LARGE VESSEL VASCULITIS: EVIDENCE TO GUIDE THE MANAGEMENT OF GIANT CELL ARTERITIS. , 2019, , .		1
70	THU0286â€™...MANAGEMENT OF TAKAYASU ARTERITIS: A SYSTEMATIC LITERATURE REVIEW INFORMING THE 2018 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF LARGE VESSEL VASCULITIS. , 2019, , .		2
71	Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis. <i>RMD Open</i> , 2019, 5, e001003.	3.8	52
72	Management of Takayasu arteritis: a systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis. <i>RMD Open</i> , 2019, 5, e001020.	3.8	56

#	ARTICLE	IF	CITATIONS
73	Spatial Distribution of Macrophages During Callus Formation and Maturation Reveals Close Crosstalk Between Macrophages and Newly Forming Vessels. <i>Frontiers in Immunology</i> , 2019, 10, 2588.	4.8	38
74	Applicability of trials in rheumatoid arthritis and osteoarthritis: A systematic review and meta-analysis of trial populations showing adequate proportion of women, but underrepresentation of elderly people. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 983-989.	3.4	21
75	Collagen I-based scaffolds negatively impact fracture healing in a mouse-osteotomy-model although used routinely in research and clinical application. <i>Acta Biomaterialia</i> , 2019, 86, 171-184.	8.3	29
76	Reply. <i>Arthritis Care and Research</i> , 2019, 71, 577-578.	3.4	0
77	Unraveling the role of hypoxia-inducible factor (HIF)-1 β and HIF-2 β in the adaption process of human microvascular endothelial cells (HMEC-1) to hypoxia: Redundant HIF-dependent regulation of macrophage migration inhibitory factor. <i>Microvascular Research</i> , 2018, 116, 34-44.	2.5	28
78	Long-term glucocorticoid treatment in patients with polymyalgia rheumatica, giant cell arteritis, or both diseases: results from a national rheumatology database. <i>Rheumatology International</i> , 2018, 38, 569-577.	3.0	43
79	Will we ever have better glucocorticoids?. <i>Clinical Immunology</i> , 2018, 186, 64-66.	3.2	24
80	Workforce requirements in rheumatology: a systematic literature review informing the development of a workforce prediction risk of bias tool and the EULAR points to consider. <i>RMD Open</i> , 2018, 4, e000756.	3.8	17
81	EULAR "points to consider"™ for the conduction of workforce requirement studies in rheumatology. <i>RMD Open</i> , 2018, 4, e000780.	3.8	16
82	Prevention of glucocorticoid morbidity in giant cell arteritis. <i>Rheumatology</i> , 2018, 57, ii11-ii21.	1.9	34
83	Prevalence of sarcopenia in systemic sclerosis: assessing body composition and functional disability in patients with systemic sclerosis. <i>Nutrition</i> , 2018, 55-56, 51-55.	2.4	37
84	Role of 11 β -HSD type 1 in abnormal HPA axis activity during immune-mediated arthritis. <i>Endocrine Connections</i> , 2018, 7, 385-394.	1.9	5
85	Harm, benefit and costs associated with low-dose glucocorticoids added to the treatment strategies for rheumatoid arthritis in elderly patients (GLORIA trial): study protocol for a randomised controlled trial. <i>Trials</i> , 2018, 19, 67.	1.6	32
86	CTLA-4 Mediates Inhibitory Function of Mesenchymal Stem/Stromal Cells. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2312.	4.1	29
87	In silico methods "Computational alternatives to animal testing. <i>ALTEX: Alternatives To Animal Experimentation</i> , 2018, 35, 126-128.	1.5	7
88	Nanocoating with plant-derived pectins activates osteoblast response in vitro. <i>International Journal of Nanomedicine</i> , 2017, Volume 12, 239-249.	6.7	17
89	The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease. <i>Rheumatology</i> , 2017, 56, kew273.	1.9	138
90	Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 543-546.	0.9	154

#	ARTICLE	IF	CITATIONS
91	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 960-977.	0.9	3,366
92	Glucocorticoids in rheumatoid arthritis: the picture is shaping up. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1785-1787.	0.9	20
93	Modified-release prednisone for polymyalgia rheumatica: a multicentre, randomised, active-controlled, double-blind, parallel-group study. <i>RMD Open</i> , 2017, 3, e000426.	3.8	19
94	Differences in biomarkers of cartilage matrix turnover and their changes over 2 years in adolescent and adult volleyball athletes. <i>Journal of Experimental Orthopaedics</i> , 2017, 4, 7.	1.8	16
95	Metabolic regulation of inflammation. <i>Nature Reviews Rheumatology</i> , 2017, 13, 267-279.	8.0	211
96	Official View on Glucocorticoids in Rheumatoid Arthritis: A Systematic Review of International Guidelines and Consensus Statements. <i>Arthritis Care and Research</i> , 2017, 69, 1134-1141.	3.4	39
97	Glucocorticoid-targeted therapies for the treatment of rheumatoid arthritis. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 187-195.	4.1	32
98	Inflammation Is an Important Covariate for the Crosstalk of Sleep and the HPA Axis in Rheumatoid Arthritis. <i>NeuroImmunoModulation</i> , 2017, 24, 11-20.	1.8	12
99	Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities. <i>Nature Reviews Rheumatology</i> , 2017, 13, 578-592.	8.0	161
100	The OMERACT Core Domain Set for Outcome Measures for Clinical Trials in Polymyalgia Rheumatica. <i>Journal of Rheumatology</i> , 2017, 44, 1515-1521.	2.0	33
101	A Pronounced Inflammatory Activity Characterizes the Early Fracture Healing Phase in Immunologically Restricted Patients. <i>International Journal of Molecular Sciences</i> , 2017, 18, 583.	4.1	45
102	Plant-derived pectin nanocoatings to prevent inflammatory cellular response of osteoblasts following <i>Porphyromonas gingivalis</i> infection. <i>International Journal of Nanomedicine</i> , 2017, Volume 12, 433-445.	6.7	9
103	Modification of the surface of superparamagnetic iron oxide nanoparticles to enable their safe application in humans. <i>International Journal of Nanomedicine</i> , 2016, Volume 11, 5883-5896.	6.7	22
104	Sustained Increase of 25-Hydroxyvitamin D Levels in Healthy Young Women during Wintertime after Three Suberythemal UV Irradiations – The MUVY Pilot Study. <i>PLoS ONE</i> , 2016, 11, e0159040.	2.5	10
105	Association Between the Use of Oral Contraceptives and Patient-Reported Outcomes in an Early Arthritis Cohort. <i>Arthritis Care and Research</i> , 2016, 68, 400-405.	3.4	5
106	Glucocorticoid therapy and body composition. <i>Nature Reviews Rheumatology</i> , 2016, 12, 444-445.	8.0	4
107	Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 952-957.	0.9	258
108	Transgenic Disruption of Glucocorticoid Signaling in Osteoblasts Attenuates Joint Inflammation in Collagen Antibody-Induced Arthritis. <i>American Journal of Pathology</i> , 2016, 186, 1293-1301.	3.8	14

#	ARTICLE	IF	CITATIONS
109	Increased Periodontal Attachment Loss in Patients With Systemic Sclerosis. <i>Journal of Periodontology</i> , 2016, 87, 763-771.	3.4	25
110	Adverse events of glucocorticoids during treatment of rheumatoid arthritis: lessons from cohort and registry studies: Table 1. <i>Rheumatology</i> , 2016, 55, ii3-ii5.	1.9	41
111	Rheumatology Workforce Planning in Western Countries: A Systematic Literature Review. <i>Arthritis Care and Research</i> , 2016, 68, 1874-1882.	3.4	27
112	Polymyalgia Rheumatica and Giant Cell Arteritis. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 2442.	7.4	346
113	Effects of PVA-coated nanoparticles on human T helper cell activity. <i>Toxicology Letters</i> , 2016, 245, 52-58.	0.8	11
114	Glucocorticoids for Management of Polymyalgia Rheumatica and Giant Cell Arteritis. <i>Rheumatic Disease Clinics of North America</i> , 2016, 42, 75-90.	1.9	38
115	Whole-body MRI undresses polymyalgia rheumatica. <i>Nature Reviews Rheumatology</i> , 2016, 12, 140-141.	8.0	1
116	Disentangling the effects of tocilizumab on neutrophil survival and function. <i>Immunologic Research</i> , 2016, 64, 665-676.	2.9	12
117	Effects of treatment with etanercept versus methotrexate on sleep quality, fatigue and selected immune parameters in patients with active rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 848-856.	0.8	8
118	Delayed-release prednisone improves fatigue and health-related quality of life: findings from the CAPRA-2 double-blind randomised study in rheumatoid arthritis. <i>RMD Open</i> , 2015, 1, e000134.	3.8	19
119	Effects of PVA coated nanoparticles on human immune cells. <i>International Journal of Nanomedicine</i> , 2015, 10, 3429.	6.7	31
120	Influence of rheumatoid arthritis-related morning stiffness on productivity at work: results from a survey in 11 European countries. <i>Rheumatology International</i> , 2015, 35, 1791-1797.	3.0	8
121	2015 Recommendations for the Management of Polymyalgia Rheumatica: A European League Against Rheumatism/American College of Rheumatology Collaborative Initiative. <i>Arthritis and Rheumatology</i> , 2015, 67, 2569-2580.	5.6	146
122	Cellular Energy Metabolism in T-Lymphocytes. <i>International Reviews of Immunology</i> , 2015, 34, 34-49.	3.3	21
123	Non-surgical management of knee osteoarthritis: where are we now and where do we need to go?. <i>RMD Open</i> , 2015, 1, e000027-e000027.	3.8	46
124	Cytokine Expression in Human Osteoblasts After Antiseptic Treatment: A Comparative Study Between Polyhexanide and Chlorhexidine. <i>Journal of Investigative Surgery</i> , 2015, 28, 1-7.	1.3	17
125	The novel strategy of glucocorticoid drug development via targeting nongenomic mechanisms. <i>Steroids</i> , 2015, 102, 27-31.	1.8	31
126	Clocking in: chronobiology in rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , 2015, 11, 349-356.	8.0	91

#	ARTICLE	IF	CITATIONS
127	2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1799-1807.	0.9	220
128	Effects of 60-day bed rest with and without exercise on cellular and humoral immunological parameters. <i>Cellular and Molecular Immunology</i> , 2015, 12, 483-492.	10.5	42
129	Systemic glucocorticoids in rheumatology. , 2015, , 423-433.		5
130	Circadian rhythms of cellular immunity in rheumatoid arthritis: a hypothesis-generating study. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 34-43.	0.8	16
131	Novel glucocorticoids: where are we now and where do we want to go?. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S29-33.	0.8	13
132	Glucocorticoids in the treatment of rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S34-6.	0.8	14
133	Autoimmune Rheumatic Diseases. <i>BioMed Research International</i> , 2014, 2014, 1-3.	1.9	4
134	Targeting IL-6 and RANKL signaling inhibits prostate cancer growth in bone. <i>Clinical and Experimental Metastasis</i> , 2014, 31, 921-933.	3.3	36
135	Direct Crosstalk Between Cancer and Osteoblast Lineage Cells Fuels Metastatic Growth in Bone via Auto-Amplification of IL-6 and RANKL Signaling Pathways. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 1938-1949.	2.8	33
136	Hydroxychloroquine in patients with inflammatory and erosive osteoarthritis of the hands (OA) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 38	1.6	25
137	Initial immune reaction and angiogenesis in bone healing. <i>Journal of Tissue Engineering and Regenerative Medicine</i> , 2014, 8, 120-130.	2.7	123
138	Unraveling the functions of the membrane-bound glucocorticoid receptors: first clues on origin and functional activity. <i>Annals of the New York Academy of Sciences</i> , 2014, 1318, 1-6.	3.8	40
139	Acute murine antigen-induced arthritis is not affected by disruption of osteoblastic glucocorticoid signalling. <i>BMC Musculoskeletal Disorders</i> , 2014, 15, 31.	1.9	9
140	NADPH oxidase 4 represents a potential target for the treatment of osteoporosis. <i>Cellular and Molecular Immunology</i> , 2014, 11, 317-319.	10.5	5
141	Impact of morning stiffness on working behaviour and performance in people with rheumatoid arthritis. <i>Rheumatology International</i> , 2014, 34, 1751-1758.	3.0	22
142	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 492-509.	0.9	1,688
143	The supplementary therapeutic DMARD role of low-dose glucocorticoids in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2014, 16, S1.	3.5	22
144	Circadian rhythms in rheumatology - a glucocorticoid perspective. <i>Arthritis Research and Therapy</i> , 2014, 16, S3.	3.5	55

#	ARTICLE	IF	CITATIONS
145	High-Sensitivity Immunofluorescence Staining: A Comparison of the Liposome Procedure and the FASER Technique on mGR Detection. <i>Journal of Fluorescence</i> , 2013, 23, 509-518.	2.5	8
146	Osteoarthritis synovial fluid activates pro-inflammatory cytokines in primary human chondrocytes. <i>International Orthopaedics</i> , 2013, 37, 145-151.	1.9	93
147	Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naïve patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 844-850.	0.9	168
148	Preoperative irradiation for the prevention of heterotopic ossification induces local inflammation in humans. <i>Bone</i> , 2013, 55, 93-101.	2.9	18
149	Optimized glucocorticoid therapy: Teaching old drugs new tricks. <i>Molecular and Cellular Endocrinology</i> , 2013, 380, 32-40.	3.2	89
150	Human immune cells' behavior and survival under bioenergetically restricted conditions in an in vitro fracture hematoma model. <i>Cellular and Molecular Immunology</i> , 2013, 10, 151-158.	10.5	40
151	Pathophysiological hypoxia affects the redox state and IL-2 signalling of human CD4 ⁺ T cells and concomitantly impairs survival and proliferation. <i>European Journal of Immunology</i> , 2013, 43, 1588-1597.	2.9	15
152	Delayed-release prednisone – a new approach to an old therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2013, 14, 1097-1106.	1.8	12
153	Gene Expression of Catalytic Proteasome Subunits and Resistance Toward Proteasome Inhibition of B Lymphocytes from Patients with Primary Sjögren Syndrome. <i>Journal of Rheumatology</i> , 2013, 40, 663-673.	2.0	10
154	Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 204-210.	0.9	160
155	A simple model that suggests possible cost savings when modified-release prednisone 5 mg/day is added to current treatment in patients with active rheumatoid arthritis. <i>Rheumatology</i> , 2013, 52, 1435-1437.	1.9	19
156	Hypoxia: how does the monocyte-macrophage system respond to changes in oxygen availability?. <i>Journal of Leukocyte Biology</i> , 2013, 95, 233-241.	3.3	55
157	Glucocorticoids. , 2013, , 1066-1076.		0
158	Symptom control with low-dose glucocorticoid therapy for rheumatoid arthritis. <i>Rheumatology</i> , 2012, 51, iv14-iv20.	1.9	10
159	The Impact of <i>Porphyromonas gingivalis</i> Lipids on Apoptosis of Primary Human Chondrocytes. <i>Connective Tissue Research</i> , 2012, 53, 327-333.	2.3	13
160	Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 75-79.	0.9	150
161	Energy metabolism and rheumatic diseases: from cell to organism. <i>Arthritis Research and Therapy</i> , 2012, 14, 216.	3.5	37
162	Limited Use of Antiseptics in Septic Surgery. <i>Journal of Investigative Surgery</i> , 2012, 25, 311-316.	1.3	6

#	ARTICLE	IF	CITATIONS
163	Human monocytes and macrophages differ in their mechanisms of adaptation to hypoxia. <i>Arthritis Research and Therapy</i> , 2012, 14, R181.	3.5	35
164	Relationship between placenta growth factor 1 and vascularization, dehydroepiandrosterone sulfate to dehydroepiandrosterone conversion, or aromatase expression in patients with rheumatoid arthritis and patients with osteoarthritis. <i>Arthritis and Rheumatism</i> , 2012, 64, 1799-1808.	6.7	8
165	Inflammatory synovial fluid microenvironment drives primary human chondrocytes to actively take part in inflammatory joint diseases. <i>Immunologic Research</i> , 2012, 52, 169-175.	2.9	32
166	Inflammatory phase of bone healing initiates the regenerative healing cascade. <i>Cell and Tissue Research</i> , 2012, 347, 567-573.	2.9	215
167	Osteoblasts mediate the adverse effects of glucocorticoids on fuel metabolism. <i>Journal of Clinical Investigation</i> , 2012, 122, 4172-4189.	8.2	163
168	Hypoxia Promotes Osteogenesis but Suppresses Adipogenesis of Human Mesenchymal Stromal Cells in a Hypoxia-Inducible Factor-1 Dependent Manner. <i>PLoS ONE</i> , 2012, 7, e46483.	2.5	157
169	A fresh look at glucocorticoids how to use an old ally more effectively. <i>Bulletin of the NYU Hospital for Joint Diseases</i> , 2012, 70 Suppl 1, 26-9.	0.7	8
170	Corticosterone selectively targets endo-cortical surfaces by an osteoblast-dependent mechanism. <i>Bone</i> , 2011, 49, 733-742.	2.9	56
171	Glucocorticoids. <i>Best Practice and Research in Clinical Rheumatology</i> , 2011, 25, 891-900.	3.3	65
172	Human Early Fracture Hematoma Is Characterized by Inflammation and Hypoxia. <i>Clinical Orthopaedics and Related Research</i> , 2011, 469, 3118-3126.	1.5	159
173	Exogenous and endogenous glucocorticoids in rheumatic diseases. <i>Arthritis and Rheumatism</i> , 2011, 63, 1-9.	6.7	87
174	Origin and functional activity of the membrane-bound glucocorticoid receptor. <i>Arthritis and Rheumatism</i> , 2011, 63, 3779-3788.	6.7	62
175	How should impaired morning function in rheumatoid arthritis be treated?. <i>Scandinavian Journal of Rheumatology</i> , 2011, 40, 28-39.	1.1	12
176	Macrophage Migration Inhibitory Factor Counterregulates Dexamethasone-Mediated Suppression of Hypoxia-Inducible Factor-1 β Function and Differentially Influences Human CD4+ T Cell Proliferation under Hypoxia. <i>Journal of Immunology</i> , 2011, 186, 764-774.	0.8	55
177	Do the treatment with glucocorticoids and/or the disease itself drive the impairment in glucose metabolism in patients with rheumatoid arthritis?. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1881-1883.	0.9	21
178	Preferred Use of Polyhexanide in Orthopedic Surgery. <i>Orthopedics</i> , 2011, 34, e664-8.	1.1	10
179	Rimexolone inhibits proliferation, cytokine expression and signal transduction of human CD4+ T-cells. <i>Immunology Letters</i> , 2010, 131, 24-32.	2.5	14
180	The selective estrogen receptor β agonist Org 37663 induces estrogenic effects but lacks antirheumatic activity: A phase IIa trial investigating efficacy and safety of Org 37663 in postmenopausal female rheumatoid arthritis patients receiving stable background methotrexate or sulfasalazine. <i>Arthritis and Rheumatism</i> , 2010, 62, 351-358.	6.7	20

#	ARTICLE	IF	CITATIONS
181	Low-dose glucocorticoid therapy in rheumatoid arthritis: an obligatory therapy. <i>Annals of the New York Academy of Sciences</i> , 2010, 1193, 123-126.	3.8	26
182	Current view of glucocorticoid co-therapy with DMARDs in rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , 2010, 6, 693-702.	8.0	116
183	Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1275-1280.	0.9	91
184	Hypothalamus-Pituitary-Adrenal Axis Function in Patients with Rheumatoid Arthritis Treated with Nighttime-Release Prednisone. <i>Journal of Rheumatology</i> , 2010, 37, 2025-2031.	2.0	85
185	The Early Fracture Hematoma and Its Potential Role in Fracture Healing. <i>Tissue Engineering - Part B: Reviews</i> , 2010, 16, 427-434.	4.8	316
186	More Night Than Day – Circadian Rhythms in Polymyalgia Rheumatica and Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2010, 37, 894-899.	2.0	27
187	Pharmacology of glucocorticoids in rheumatoid arthritis. <i>Current Opinion in Pharmacology</i> , 2010, 10, 302-307.	3.5	38
188	Osteoblast-targeted disruption of glucocorticoid signalling does not delay intramembranous bone healing. <i>Steroids</i> , 2010, 75, 282-286.	1.8	13
189	The association between rheumatoid arthritis and periodontal disease. <i>Arthritis Research and Therapy</i> , 2010, 12, 218.	3.5	184
190	Inflammation, glucocorticoids and risk of cardiovascular disease. <i>Nature Clinical Practice Rheumatology</i> , 2009, 5, 18-19.	3.2	18
191	Adaptation of Human CD4+ T Cells to Pathophysiological Hypoxia: A Transcriptome Analysis. <i>Journal of Rheumatology</i> , 2009, 36, 2655-2669.	2.0	42
192	Cellular composition of the initial fracture hematoma compared to a muscle hematoma: A study in sheep. <i>Journal of Orthopaedic Research</i> , 2009, 27, 1147-1151.	2.3	78
193	Transgenic disruption of glucocorticoid signaling in mature osteoblasts and osteocytes attenuates K/BxN mouse serum-induced arthritis in vivo. <i>Arthritis and Rheumatism</i> , 2009, 60, 1998-2007.	6.7	49
194	The challenge of continuous exogenous glucocorticoid administration in mice. <i>Steroids</i> , 2009, 74, 245-249.	1.8	36
195	Human CD4+ T cells maintain specific functions even under conditions of extremely restricted ATP production. <i>European Journal of Immunology</i> , 2008, 38, 1631-1642.	2.9	40
196	Genomic and nongenomic effects of glucocorticoids. <i>Nature Clinical Practice Rheumatology</i> , 2008, 4, 525-533.	3.2	456
197	Chapter 20 Hormonal Modulation of Autoimmune Diseases: Glucocorticoids. <i>Handbook of Systemic Autoimmune Diseases</i> , 2008, 9, 229-240.	0.1	0
198	Novel insights into mechanisms of glucocorticoid action and the development of new glucocorticoid receptor ligands. <i>Steroids</i> , 2008, 73, 1025-1029.	1.8	180

#	ARTICLE	IF	CITATIONS
199	Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. <i>Lancet</i> , The, 2008, 371, 205-214.	13.7	340
200	Glucocorticoids. , 2008, , 644-650.		1
201	Circadian rhythms of nocturnal hormones in rheumatoid arthritis: translation from bench to bedside. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 905-908.	0.9	57
202	A case of Erdheimâ€“Chester disease initially mistaken for Ormond's disease. <i>Nature Clinical Practice Rheumatology</i> , 2008, 4, 50-55.	3.2	11
203	Glucocorticoids. , 2008, , 644-650.		3
204	Glucocorticoids. , 2008, , 1293-1305.		2
205	Arthritis and endogenous glucocorticoids: the emerging role of the 11ÂˆHSD enzymes. <i>Annals of the Rheumatic Diseases</i> , 2007, 67, 1201-1203.	0.9	13
206	Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists. <i>Molecular and Cellular Endocrinology</i> , 2007, 275, 71-78.	3.2	328
207	Non-genomic glucocorticoid effects to provide the basis for new drug developments. <i>Molecular and Cellular Endocrinology</i> , 2006, 246, 142-146.	3.2	178
208	Effects of tacrolimus, cyclosporin A and sirolimus on MG63 cells. <i>Transplant International</i> , 2006, 19, 563-569.	1.6	14
209	Glucocorticoids cause rapid dissociation of a Tâ€“cellâ€“receptorâ€“associated protein complex containing LCK and FYN. <i>EMBO Reports</i> , 2006, 7, 1023-1029.	4.5	135
210	Correlation of different bone markers with bone density in patients with rheumatic diseases on glucocorticoid therapy. <i>Rheumatology International</i> , 2006, 26, 331-336.	3.0	10
211	Development of cervical interspinous bursitis after prolonged sports trauma: a case report. <i>Joint Bone Spine</i> , 2006, 73, 118-120.	1.6	7
212	Potencies of topical glucocorticoids to mediate genomic and nongenomic effects on human peripheral blood mononuclear cells. <i>Biochemical Pharmacology</i> , 2006, 71, 530-539.	4.4	11
213	Membrane glucocorticoid receptor expression on peripheral blood mononuclear cells in patients with ankylosing spondylitis. <i>Journal of Rheumatology</i> , 2006, 33, 2249-53.	2.0	13
214	Rapid immunosuppressive effects of glucocorticoids mediated through Lck and Fyn. <i>Blood</i> , 2005, 106, 1703-1710.	1.4	145
215	Oxygen consumption and mitochondrial membrane potential indicate developmental adaptation in energy metabolism of rat cortical neurons. <i>European Journal of Neuroscience</i> , 2005, 21, 2721-2732.	2.6	20
216	Current use of glucocorticoids in patients with rheumatoid arthritis in Germany. <i>Arthritis and Rheumatism</i> , 2005, 53, 740-747.	6.7	48

#	ARTICLE	IF	CITATIONS
217	Tumoral calcinosis revisited: pathophysiology and treatment. <i>Rheumatology International</i> , 2005, 25, 55-59.	3.0	37
218	Optimised glucocorticoid therapy: the sharpening of an old spear. <i>Lancet</i> , The, 2005, 365, 801-803.	13.7	124
219	Developments in Glucocorticoid Therapy. <i>Rheumatic Disease Clinics of North America</i> , 2005, 31, 1-17.	1.9	34
220	New glucocorticoids on the horizon: repress, don't activate!. <i>Journal of Rheumatology</i> , 2005, 32, 1199-1207.	2.0	36
221	Membrane glucocorticoid receptors (mGCR) are expressed in normal human peripheral blood mononuclear cells and upregulated after in vitro stimulation and in patients with rheumatoid arthritis. <i>FASEB Journal</i> , 2004, 18, 70-80.	0.5	183
222	Glucocorticoids in the treatment of rheumatic diseases: An update on the mechanisms of action. <i>Arthritis and Rheumatism</i> , 2004, 50, 3408-3417.	6.7	294
223	Nonsteroidal antiinflammatory drugs and a selective cyclooxygenase 2 inhibitor uncouple mitochondria in intact cells. <i>Arthritis and Rheumatism</i> , 2003, 48, 1438-1444.	6.7	69
224	Quantitating Protein Synthesis, Degradation, and Endogenous Antigen Processing. <i>Immunity</i> , 2003, 18, 343-354.	14.3	461
225	Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2002, 61, 718-722.	0.9	395
226	Rapid glucocorticoid effects on immune cells. <i>Steroids</i> , 2002, 67, 529-534.	1.8	254
227	Effects of Norepinephrine on Oxygen Consumption of Quiescent and Activated Human Peripheral Blood Mononuclear Cells. <i>Annals of the New York Academy of Sciences</i> , 2002, 966, 365-368.	3.8	7
228	Gastrointestinal toxic side effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2-specific inhibitors. <i>American Journal of Medicine</i> , 2001, 110, 13-19.	1.5	97
229	Signaling Takes a Breath – New Quantitative Perspectives on Bioenergetics and Signal Transduction. <i>Immunity</i> , 2001, 15, 497-502.	14.3	124
230	Short-Term Effects of the 21-Aminosteroid Lazaroid Tirilazad Mesylate (PNU-74006F) and the Pyrrolopyrimidine Lazaroid PNU-101033E on Energy Metabolism of Human Peripheral Blood Mononuclear Cells. <i>Bioscience Reports</i> , 2001, 21, 101-110.	2.4	6
231	Mechanism of action of glucocorticosteroid hormones: possible implications for therapy of neuroimmunological disorders. <i>Journal of Neuroimmunology</i> , 2001, 117, 1-8.	2.3	126
232	Effect of Glucocorticoid Therapy on Glucocorticoid Receptors in Children with Autoimmune Diseases. <i>Pediatric Research</i> , 2001, 49, 130-135.	2.3	31
233	Bioenergetics of immune functions: fundamental and therapeutic aspects. <i>Trends in Immunology</i> , 2000, 21, 194-199.	7.5	239
234	Therapeutically targeting lymphocyte energy metabolism by high-dose glucocorticoids. <i>Biochemical Pharmacology</i> , 2000, 59, 597-603.	4.4	23

#	ARTICLE	IF	CITATIONS
235	Bioenergetics of Human Peripheral Blood Mononuclear Cell Metabolism in Quiescent, Activated, and Glucocorticoid-Treated States. <i>Bioscience Reports</i> , 2000, 20, 289-302.	2.4	70
236	The influence of obesity on perioperative morbidity and mortality in revision total hip arthroplasty. <i>Archives of Orthopaedic and Trauma Surgery</i> , 2000, 120, 267-271.	2.4	69
237	Higher expression of glucocorticoid receptor in peripheral mononuclear cells in inflammatory bowel disease. <i>American Journal of Gastroenterology</i> , 2000, 95, 1994-1999.	0.4	41
238	Equivalent doses and relative drug potencies for non-genomic glucocorticoid effects: a novel glucocorticoid hierarchy. <i>Biochemical Pharmacology</i> , 1999, 58, 363-368.	4.4	134
239	Effects of the mitogen concanavalin A on pathways of thymocyte energy metabolism. <i>Biochimica Et Biophysica Acta - Bioenergetics</i> , 1999, 1412, 129-138.	1.0	37
240	A new hypothesis of modular glucocorticoid actions: Steroid treatment of rheumatic diseases revisited. <i>Arthritis and Rheumatism</i> , 1998, 41, 761-767.	6.7	209
241	Clinical Image: Isolated arteritis of the superior mesenteric artery with positive perinuclear antineutrophil cytoplasmic antibody. <i>Arthritis and Rheumatism</i> , 1998, 41, 1701-1701.	6.7	3
242	Methylprednisolone inhibits uptake of Ca ²⁺ and Na ⁺ ions into concanavalin A-stimulated thymocytes. <i>Biochemical Journal</i> , 1997, 326, 329-332.	3.7	50
243	Reply: To the editor. <i>Arthritis and Rheumatism</i> , 1997, 40, 1185-1186.	6.7	0
244	Reply: Finger exostosis caused by drumming? Comment on the clinical image report by Buttgereit and Burmester. <i>Arthritis and Rheumatism</i> , 1997, 40, 1185-1186.	6.7	0
245	Clinical images: Drummer's finger. <i>Arthritis and Rheumatism</i> , 1996, 39, 1258-1258.	6.7	1
246	The influence of Methylprednisolone on the energy metabolism of Ehrlich ascites tumour cells. <i>Bioscience Reports</i> , 1994, 14, 283-290.	2.4	3
247	The effects of methylprednisolone on oxidative phosphorylation in Concanavalin-A-stimulated thymocytes. Top-down elasticity analysis and control analysis. <i>FEBS Journal</i> , 1994, 223, 513-519.	0.2	50
248	Effects of methylprednisolone on the energy metabolism of quiescent and conA-stimulated thymocytes of the rat. <i>Bioscience Reports</i> , 1993, 13, 41-52.	2.4	28
249	Quantification of ATP-producing and consuming processes of Ehrlich ascites tumour cells. <i>FEBS Journal</i> , 1986, 161, 701-705.	0.2	63
250	A new hypothesis of modular glucocorticoid actions: Steroid treatment of rheumatic diseases revisited. , 0, .		2